• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Nicotine Addiction: What Lights Up the Field

Pharmaceutical ExecutivePharmaceutical Executive-12-01-2010
Volume 0
Issue 0

Pharm Exec's Pipeline Report 2018

The market for anti-smoking products exceeds $2 billion, but their superiority over cold-turkey quitting remains controversial. The first vaccines are set to offer a new weapon in the fight against nicotine addiction. Long-lasting single injections, these new vaccines remove the hurdle of daily adherence while sparking the immune system to produce nicotine-specific antibodies that aggregate nicotine in the bloodstream, resulting in a nicotine complex too large to cross the blood-brain barrier where the reward system awaits. Denying the pleasure of the fix may indirectly help minimize the craving that accompanies quitting smoking. Although Nabi Biopharma/GSK's NicVAX is on schedule to beat Novartis' NIC-002 to market, the Swiss firm's vax is expected to grab a larger market share because of its greater efficacy—and Novartis' marketing muscle, says Datamonitor's Ben Greenacre.

Recent Videos
Related Content